Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies
© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC..
BACKGROUND: Chimeric antigen receptor (CAR)-T-cell therapies have revolutionized the management of acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma but come at the price of unique toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and long-term "on-target off-tumor" effects.
METHODS: All of these factors increase infection risk in an already highly immunocompromised patient population. Indeed, infectious complications represent the key determinant of non-relapse mortality after CAR-T cells. The temporal distribution of these risk factors shapes different infection patterns early versus late post-CAR-T-cell infusion. Furthermore, due to the expression of their targets on B lineage cells at different stages of differentiation, CD19, and B-cell maturation antigen (BCMA) CAR-T cells induce distinct immune deficits that could require different prevention strategies. Infection incidence is the highest during the first month post-infusion and subsequently decreases thereafter. However, infections remain relatively common even a year after infusion.
RESULTS: Bacterial infections predominate early after CD19, while a more equal distribution between bacterial and viral causes is seen after BCMA CAR-T-cell therapy, and fungal infections are universally rare. Cytomegalovirus (CMV) and other herpesviruses are increasingly breported, but whether routine monitoring is warranted for all, or a subgroup of patients, remains to be determined. Clinical practices vary substantially between centers, and many areas of uncertainty remain, including CMV monitoring, antibacterial and antifungal prophylaxis and duration, use of immunoglobulin replacement therapy, and timing of vaccination.
CONCLUSION: Risk stratification tools are available and may help distinguish between infectious and non-infectious causes of fever post-infusion and predict severe infections. These tools need prospective validation, and their integration in clinical practice needs to be systematically studied.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 Suppl 1 |
|---|---|
| Enthalten in: |
Transplant infectious disease : an official journal of the Transplantation Society - 25 Suppl 1(2023) vom: 03. Nov., Seite e14157 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kampouri, Eleftheria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B-Cell Maturation Antigen |
|---|
| Anmerkungen: |
Date Completed 11.12.2023 Date Revised 11.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/tid.14157 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362811784 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362811784 | ||
| 003 | DE-627 | ||
| 005 | 20231227131659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tid.14157 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM362811784 | ||
| 035 | |a (NLM)37787373 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kampouri, Eleftheria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2023 | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Chimeric antigen receptor (CAR)-T-cell therapies have revolutionized the management of acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma but come at the price of unique toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and long-term "on-target off-tumor" effects | ||
| 520 | |a METHODS: All of these factors increase infection risk in an already highly immunocompromised patient population. Indeed, infectious complications represent the key determinant of non-relapse mortality after CAR-T cells. The temporal distribution of these risk factors shapes different infection patterns early versus late post-CAR-T-cell infusion. Furthermore, due to the expression of their targets on B lineage cells at different stages of differentiation, CD19, and B-cell maturation antigen (BCMA) CAR-T cells induce distinct immune deficits that could require different prevention strategies. Infection incidence is the highest during the first month post-infusion and subsequently decreases thereafter. However, infections remain relatively common even a year after infusion | ||
| 520 | |a RESULTS: Bacterial infections predominate early after CD19, while a more equal distribution between bacterial and viral causes is seen after BCMA CAR-T-cell therapy, and fungal infections are universally rare. Cytomegalovirus (CMV) and other herpesviruses are increasingly breported, but whether routine monitoring is warranted for all, or a subgroup of patients, remains to be determined. Clinical practices vary substantially between centers, and many areas of uncertainty remain, including CMV monitoring, antibacterial and antifungal prophylaxis and duration, use of immunoglobulin replacement therapy, and timing of vaccination | ||
| 520 | |a CONCLUSION: Risk stratification tools are available and may help distinguish between infectious and non-infectious causes of fever post-infusion and predict severe infections. These tools need prospective validation, and their integration in clinical practice needs to be systematically studied | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BCMA | |
| 650 | 4 | |a CAR-T-cell therapy | |
| 650 | 4 | |a CD19 | |
| 650 | 4 | |a infections | |
| 650 | 4 | |a prediction | |
| 650 | 4 | |a prevention | |
| 650 | 4 | |a risk stratification | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a cell-associated neurotoxicity |2 NLM | |
| 650 | 7 | |a B-Cell Maturation Antigen |2 NLM | |
| 700 | 1 | |a Little, Jessica S |e verfasserin |4 aut | |
| 700 | 1 | |a Rejeski, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Manuel, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a Hammond, Sarah P |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Joshua A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant infectious disease : an official journal of the Transplantation Society |d 1999 |g 25 Suppl 1(2023) vom: 03. Nov., Seite e14157 |w (DE-627)NLM113005482 |x 1399-3062 |7 nnns |
| 773 | 1 | 8 | |g volume:25 Suppl 1 |g year:2023 |g day:03 |g month:11 |g pages:e14157 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tid.14157 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 Suppl 1 |j 2023 |b 03 |c 11 |h e14157 | ||